Rheumatoid arthritis is an inflammatory disease that is chronic nature. Causes significant damage to joints and leads to the inflammatory SYNOVITIS cartilage can destroy articulate and joints ankylosis completely, along with that affects many other organs and tissues.
With more than 40 million Americans without health insurance and nearly 2 million suffering from rheumatoid arthritis, a large number of patients are unable to pay for health care for the medicines needed to combat the symptoms of this disease. To resolve this problem, a number of large pharmaceutical companies have introduced the patient assistance programs. These programs are designed to help those patients who are unable to pay all the medicines needed to combat rheumatoid arthritis.
While some given medicine at a very low cost, others are offered them for free. The companies that produce medicines to this condition run such programs for mainly two reasons, in order to fulfil its social responsibility and use it as a platform for the effectiveness of these drugs market. Whatever the reason for the introduction of programmes of assistance to the patient, there is no denying its usefulness, especially those who suffer from rheumatoid arthritis and cannot afford adequate medical treatment.
The pharmaceutical companies that offer assistance programmes to the patient for rheumatoid arthritis, make it according to its own regulations. They selected medications that can offer these programs, and also have some rules on the selection of patients who can benefit from these programmes, depending on your financial situation and medical history.
